Deutetrabenazine, sold under the brand name Austedo, is a vesicular monoamine transporter 2 inhibitor which is used for the treatment of chorea associated with Huntington's disease and tardive dyskinesia.

The precise mechanism of action of deutetrabenazine in mediating its anti-chorea effects is not fully elucidated. Deutetrabenazine reversibly depletes the levels of monoamines, such as dopamine, …

Jul 17, 2024 · In summary, Deutetrabenazine works by inhibiting the VMAT2 protein, thereby reducing the release of neurotransmitters like dopamine in the brain. Its deuterated structure prolongs the …

AUSTEDO XR and AUSTEDO can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease. Anyone considering the use of AUSTEDO XR or …

Jun 20, 2025 · Although the precise mechanism of action of deutetrabenazine for the treatment of tardive dyskinesia is unknown, it is thought to relate to its ability to deplete monoamines from nerve …

Feb 10, 2025 · Deutetrabenazine is contraindicated in patients with Huntington's disease who are suicidal or have untreated or inadequately treated depression. A vesicular monoamine transporter 2 …

Aug 6, 2023 · The mode of action of Austedo is not clear, but it is believed to involve the reversible depletion of monoamines (dopamine, serotonin, norepinephrine, and histamine) from the nerve …

The exact mechanism of deutetrabenazine’s anti-chorea effects is unknown, but it is believed to be related to the reversible monoamine depletion

Parkinsonism: AUSTEDO XR and AUSTEDO may cause parkinsonism in patients with Huntington’s disease or tardive dyskinesia. Parkinsonism has also been observed with other VMAT2 inhibitors.

Vesicular monoamine transporter 2 (VMAT2) is a protein that regulates the packaging and release of monoamines (dopamine, serotonin, norepinephrine, and histamine). VMAT2 inhibitors decrease …